scispace - formally typeset
H

Hongguang Huo

Researcher at Harvard University

Publications -  12
Citations -  7409

Hongguang Huo is an academic researcher from Harvard University. The author has contributed to research in topics: Induced pluripotent stem cell & Embryonic stem cell. The author has an hindex of 9, co-authored 12 publications receiving 7127 citations. Previous affiliations of Hongguang Huo include Boston Children's Hospital & Howard Hughes Medical Institute.

Papers
More filters
Journal ArticleDOI

Reprogramming of human somatic cells to pluripotency with defined factors

TL;DR: The data demonstrate that defined factors can reprogramme human cells to pluripotency, and establish a method whereby patient-specific cells might be established in culture.
Journal ArticleDOI

Disease-Specific Induced Pluripotent Stem Cells

TL;DR: The generation of induced pluripotent stem cells from patients with a variety of genetic diseases with either Mendelian or complex inheritance are described, offering an unprecedented opportunity to recapitulate both normal and pathologic human tissue formation in vitro, thereby enabling disease investigation and drug development.
Journal ArticleDOI

Generation of induced pluripotent stem cells from human blood

TL;DR: The ability to reprogram cells from human blood will allow the generation of patient-specific stem cells for diseases in which the disease-causing somatic mutations are restricted to cells of the hematopoietic lineage.
Journal ArticleDOI

Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells

TL;DR: Using serial live imaging of human fibroblasts undergoing reprogramming to identify distinct colony types that morphologically resemble embryonic stem cells yet differ in molecular phenotype and differentiation potential, it is determined that only one colony type represents true iPS cells, whereas the others represent reprograming intermediates.
Journal ArticleDOI

Generation of human-induced pluripotent stem cells

TL;DR: This protocol describes how to establish primary human fibroblasts lines and how to derive iPS cells by retroviral transduction of reprogramming factors, and takes 2 months to complete reprograming human primary fibro Blasts starting from biopsy.